Skip to main content

Table 1 Type of systemic therapies employed as the immediate subsequent therapeutic line after TREnd (physician choice), classified by pharmacological classes

From: Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

  Number
Subsequent chemotherapy (n = 69, 66%)
 Capecitabine-containing (n = 30) Capecitabine 22
Capecitabine + vinorelbine 6
Capecitabine + vinorelbine + cyclophosphamide 2
 Taxane-based (n = 21) Paclitaxel 20
Paclitaxel + BYL79* 1
 Anthracycline-based (n = 9) Doxorubicin 1
Epirubicin 1
Doxorubicin + cyclophosphamide 7
 Platinum-containing (n = 2) Cisplatin 1
Cisplatin + cyclophosphamide 1
 Others (n = 7) Vinorelbine 3
Cyclophosphamide + methotrexate 2
Cyclophosphamide + vinorelbine 2
Subsequent endocrine therapy (n = 33, 31%)
 Fulvestrant (n = 20)   20
 AIs (n = 7) Letrozole 2
Anastrozole 1
Exemestane 4
 AI + mTORi (n = 6) Exemestane + everolimus 5
Exemestane + everolimus + BYL719* 1
Subsequent other targeted/novel therapies (n = 3, 3%)
 Lucitanib 1
 Ribociclib (single agent) 1
 64-Cu-asparagine 1
  1. AIs aromatase inhibitors, mTORi inhibitors of mammalian target of rapamycin
  2. *BYL719 = alpelisib (PI3K inhibitor)